Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Evaluating the Pharmacokinetics and Safety of Miricorilant (NCT07553663) | Corcept Therapeutics | 2026-04-30 |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (NCT06419374) | 89bio, Inc. | 2024-05-24 |
Track Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis automatically
Every clearance here is in the API, with alerts when new ones post.